Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02822963

Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
National Cheng-Kung University Hospital · Academic / Other
Sex
Male
Age
20 Years
Healthy volunteers
Not accepted

Summary

Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.

Conditions

Timeline

Start date
2016-03-01
Primary completion
2016-07-01
Completion
2016-08-01
First posted
2016-07-06
Last updated
2020-10-06

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02822963. Inclusion in this directory is not an endorsement.